Press releases
- Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
- Theravance Biopharma to Participate in an Upcoming Investor Conference
- Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
- Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
- Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
More ▼
Key statistics
On Friday, Theravance Biopharma Inc (0TB:DUS) closed at 8.65, 14.57% above the 52 week low of 7.55 set on Feb 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.75 |
---|---|
High | 8.85 |
Low | 8.65 |
Bid | 8.45 |
Offer | 8.65 |
Previous close | 8.75 |
Average volume | 0.00 |
---|---|
Shares outstanding | 48.56m |
Free float | 41.37m |
P/E (TTM) | -- |
Market cap | 466.18m USD |
EPS (TTM) | -0.861 USD |
Data delayed at least 15 minutes, as of May 17 2024 18:30 BST.
More ▼